Moleculin Biotech
MBRX
MBRX
23 hedge funds and large institutions have $1.78M invested in Moleculin Biotech in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-1
Holders Change %
-4.17%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
$294K |
| 2 |
AC
Armistice Capital
New York
|
$179K |
| 3 |
Renaissance Technologies
New York
|
$127K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$647K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
$113K |
Top Sellers
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
$0 |
| 2 |
Citadel Advisors
Miami,
Florida
|
$0 |
| 3 |
TSS
Two Sigma Securities
New York
|
$0 |
| 4 |
VF
Virtu Financial
New York
|
$0 |
| 5 |
BlackRock
New York
|
$39K |
